Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 3/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.43 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.42 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.41 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.41 |
| ▸ | PTGFR | P43088 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27868603 | 1.00 | TBXA2R (0.50) | TBXA2RFOLH1LMNAAOC3SLC18A3 | |
| SCHEMBL2743522 | 1.00 | TBXA2R (0.50) | TBXA2RFOLH1LMNAAOC3SLC18A3 | |
| SCHEMBL8743003 | 0.93 | TBXA2R (0.58) | TBXA2RPTGER2PTGER1PTGFR | |
| SCHEMBL8742992 | 0.93 | TBXA2R (0.58) | TBXA2RPTGER2PTGER1PTGFR | |
| SCHEMBL21358345 | 0.91 | FOLH1 (0.46) | TBXA2RFOLH1AOC3 | |
| SCHEMBL641514 | 0.91 | FOLH1 (0.46) | TBXA2RFOLH1AOC3 | |
| SCHEMBL67079 | 0.87 | TBXA2R (0.58) | TBXA2RFOLH1LMNA | |
| SCHEMBL11756883 | 0.86 | FFAR1 (0.48) | TBXA2RFOLH1AOC3 | |
| SCHEMBL4311004 | 0.85 | AOC3 (0.47) | AOC3 | |
| SCHEMBL28412576 | 0.84 | NPC1 (0.41) | TBXA2RFOLH1PTGER1PTGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103849574-B | Candida parapsilosis ZJPH1305 and the application in chiral alcohol preparation | JIANG University OF TECHNOLOGY (CN) | 2016-03-02 | — | — | CN | claimed |
| CN-103849574-A | Candida parapsilosis ZJPH1305 and application thereof in preparation of chiral alcohol | UNIV ZHEJIANG TECHNOLOGY | 2014-06-11 | — | — | CN | claimed |
| US-9994520-B2 | Enzymatic process for the preparation of (S)-5-(4-fluoro-phenyl)-5-hydroxy-1morpholin-4-yl-pentan-1-one, an intermediate of ezetimibe and further conversion to ezetimibe | MYLAN LABORATORIES LIMITED (IN) | 2018-06-12 | — | — | US | disclosed |
| CN-103849574-B | Candida parapsilosis ZJPH1305 and the application in chiral alcohol preparation | JIANG University OF TECHNOLOGY (CN) | 2016-03-02 | — | — | CN | disclosed |
| CN-103849574-B | Candida parapsilosis ZJPH1305 and the application in chiral alcohol preparation | JIANG University OF TECHNOLOGY (CN) | 2016-03-02 | — | — | CN | disclosed |
| CN-103896700-B | The preparation method of ezetimibe chiral intermediate | ZHEJIANG JIUZHOU PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2015-12-23 | — | — | CN | disclosed |
| CN-103896700-A | Preparation method of ezetimibe chiral intermediate | ZHEJIANG JIUZHOU PHARMACEUTICAL TECHNOLOGY CO LTD | 2014-07-02 | — | — | CN | disclosed |
| CN-103849574-A | Candida parapsilosis ZJPH1305 and application thereof in preparation of chiral alcohol | UNIV ZHEJIANG TECHNOLOGY | 2014-06-11 | — | — | CN | disclosed |
| CN-102605034-B | Biological enzyme resolution method for preparing optically pure (S)-5-(4-fluorophenyl)-5-hydroxypentanoate | CHONGQING HUIJIAN BIOLOG TECHNOLOGY CO LTD | 2014-05-14 | — | — | CN | disclosed |
| CN-102605034-B | Biological enzyme resolution method for preparing optically pure (S)-5-(4-fluorophenyl)-5-hydroxypentanoate | CHONGQING HUIJIAN BIOLOG TECHNOLOGY CO LTD | 2014-05-14 | — | — | CN | disclosed |
| CN-102605034-B | Biological enzyme resolution method for preparing optically pure (S)-5-(4-fluorophenyl)-5-hydroxypentanoate | CHONGQING HUIJIAN BIOLOG TECHNOLOGY CO LTD | 2014-05-14 | — | — | CN | disclosed |
| CN-102605034-A | Biological enzyme resolution method for preparing optically pure (S)-5-(4-fluorophenyl)-5-hydroxypentanoate | CHONGQING HUIJIAN BIOLOG TECHNOLOGY CO LTD | 2012-07-25 | — | — | CN | disclosed |
| CN-102605034-A | Biological enzyme resolution method for preparing optically pure (S)-5-(4-fluorophenyl)-5-hydroxypentanoate | CHONGQING HUIJIAN BIOLOG TECHNOLOGY CO LTD | 2012-07-25 | — | — | CN | disclosed |
| WO-2005066120-A2 | PROCESS FOR ASYMMETRIC SYNTHESIS OF HYDROXY-ALKYL SUBSTITUTED AZETIDINONE DERIVATIVES | RANBAXY LABORATORIES LIMITED (IN) | 2005-07-21 | — | — | WO | disclosed |
| US-6906063-B2 | Platelet ADP receptor inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2005-06-14 | — | — | US | disclosed |
| EP-0862645-B1 | STEREOSELECTIVE MICROBIAL REDUCTION PROCESS | SCHERING CORP (US) | 2003-02-05 | — | — | EP | disclosed |
| US-20020077486-A1 | For therapy and prophylaxis of thrombosis in a mammal | ALEXION PHARMACEUTICALS, INC. | 2002-06-20 | — | — | US | disclosed |
| EP-0862645-A1 | STEREOSELECTIVE MICROBIAL REDUCTION PROCESS | SCHERING CORPORATION (US) | 1998-09-09 | — | — | EP | disclosed |
| US-5618707-A | CHEMICAL INTERMEDIATE FOR ANTICHOLESTEROL AGENT | SCHERING CORPORATION (US) | 1997-04-08 | — | — | US | disclosed |
| WO-1997012053-A1 | STEREOSELECTIVE MICROBIAL REDUCTION PROCESS | SCHERING CORPORATION (US) | 1997-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077486-A1 | For therapy and prophylaxis of thrombosis in a mammal | PIGS, TBXA2R, GP6 | TBXA2R 2/4885FOLH1 2475/4885LMNA 2940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.